Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 24, Issue 4, 2009, Pages 1082-1088

  Vaziri, Nosratola D ^a,c   Zhou, Xin J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Cardiovascular disease; Erythropoietin; Progression of CKD; Vascular access thrombosis

Indexed keywords

ERYTHROPOIETIN; IRON; N(G),N(G) DIMETHYLARGININE;

ADVERSE OUTCOME; AMINO ACID SYNTHESIS; ANEMIA; ANGIOGENESIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CELL GROWTH; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; HEMODIALYSIS; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; THROMBOCYTE COUNT; VASCULAR SMOOTH MUSCLE;

ANEMIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; ERYTHROPOIETIN; HEMATINICS; HUMANS; KIDNEY DISEASES;

EID: 65349168039     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn601     Document Type: Editorial

References (87)

1. Besarab A. Anemia of renal disease in diseases of kidney and urinary tract. In: Schrier RW (ed). Diseases of the Kidney and Urinary Tract, 7th edn. Philadelphia, PA: Lippincott, Williams and Company, 2001, 2719-2734
2. Locatelli F, Andrulli S, Memoli B et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006; 2: 991-998
3. Herrera J,NavaM, RomeroFet al.Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001; 37: 750-757
4. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int2004; 65: 1802-1809
5. Lim PS,Wei YH,YuYLet al. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant1999; 14: 2680-2687
6. CollinsAJ, Li S, St PeterWet al.Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465-2473
7. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int2004; 65: 626-633
8. Robinson BM, Joffe MM, Berns J et al. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 2005; 68: 2323-2330
9. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis patients of five European countries: association with morbidity andmortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132
10. Wolfe RA, Hulbert-Shearon TE, Ashby VB et al. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. Am J Kidney Dis 2005; 45: 127-135
11. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl JMed 1998; 339: 584-590
12. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
13. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
14. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388
15. Parfrey PS. Target hemoglobin level for EPO therapy in CKD. Am J Kidney Dis 2006; 47: 171-173
16. NKF-K/DOQI. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 474
17. Himmelfarb J, Stenvinkel P, Ikizler TA et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538
18. Vaziri ND. Oxidative stress in uremia. Nature, mechanisms and potential consequences. Semin Nephrol 2004; 24: 469-473
19. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695
20. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 2004; 13: 125-138
21. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007; 18: 427-434
22. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 2007; 18: 394-400
23. Kuo CC, Lee CT, Chuang CH et al. Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis. Clin Nephrol 2005; 63: 92-97
24. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008
25. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33: 821-828
26. Vaziri ND. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 2001; 10: 633-637
27. Vaziri ND, Zhou XJ, Naqvi F et al. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol (Endocrinol Metab) 1996; 271: E113-E122
28. Vaziri ND, Zhou XJ, Smith J et al. In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol (Renal Fluid Electrolyte Physiol)1995; 269: F838-F845
29. Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 1994; 4: 1874-1878
30. NeusserM, Tepel M, ZidekW. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 1993; 27: 1233-1236
31. Takahashi K, Totsune K, Imai Y et al. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci 1993; 84: 47-50
32. Bode-B̈oger SM, B̈oger RH, Kuhn M et al. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996; 50: 1255-1261
33. Carlini RG, Dusso AS, Obialo CI et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993; 43: 1010-1014
34. Eggena P, Willsey P, Jamgotchian N et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 1991; 261: E642-E646
35. Barrett JD, Zhang Z, Zhu JH et al. Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens 1998; 16: 1749-1757
36. Kuriyama S, Tomonari H, Tokudome G et al. Association of angiotensinogen gene polymorphism with erythropoietin-induced hypertension: a preliminary report. Hypertens Res 2001; 24: 501-505
37. Lebel M, Rodrigue ME, Agharazii M et al. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens 2006; 19: 1286- 1292
38. Rodrigue ME, Moreau C, Larivi'ere R et al. Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietininduced hypertension in uremic rats. J Cardiovasc Pharmacol 2003; 41: 388-395
39. Rodrigue ME, Lacasse-M S, Larivi'ere R et al. Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats. Can J Physiol Pharmacol 2005; 83: 467-475
40. Anagnostou A, Lee ES, Kessimian N et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-5982
41. Ammarguellat F, Gogusev J, Dr̈ueke TB. Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant 1996; 11: 687-692
42. Akimoto T, Kusano E, Ito C et al. Involvement of erythropoietininduced cytosolic free calcium mobilization in activation of mitogenactivated protein kinase andDNAsynthesis in vascular smoothmuscle cells. J Hypertens 2001; 19: 193-202
43. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47: 740-745
44. Satoh K, Kagaya Y, Nakano M et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006; 113: 1442-1450
45. Yatsiv I, Grigoriadis N, Simeonidou C et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J 2005; 19: 1701-1703
46. Van Der Meer P, Lipsic E, Henning RH et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 2004; 6: 853- 859
47. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol (Renal Physiol)1994; 266: F360-F366
48. Kase S, Saito W, Ohgami K et al. Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy. Br J Ophthalmol 2007; 91: 1376-1378
49. Nagarajan S, Mansfield E, Hsieh S et al. Transplant reno-vascular stenoses associated with early erythropoietin use. Clin Transplant2007; 21: 597-608
50. Bittorf T, B̈uchse T, Sasse T et al.Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance. Cell Signal 2001; 13: 673-681
51. Chen HC, Tsai JC, Tsai JH et al. Recombinant human erythropoietin enhances superoxide production by FMLP-stimulated polymorphonuclear leukocytes in hemodialysis patients. Kidney Int 1997; 52: 1390-1394
52. Kaupke CJ, Butler GC, Vaziri ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 1996; 3: 1672-1679
53. Zhou XJ, Vaziri ND. Defective calcium signaling in uremic platelets and its amelioration with long-term erythropoietin therapy. Nephro Dial Transpl 2002; 17: 992-997
54. Kahraman S, Yilmaz R, Kirkpantur A et al. Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology 2005; 10: 264-269
55. Nagai T, Akizawa T, Kohjiro S et al. rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells. Kidney Int 1996; 50: 102-107
56. Borawski J, Naumnik B, Mysliwiec M. Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy. Clin Appl Thromb Hemost2002; 8: 359-367
57. Fust'e B, Serradell M, Escolar G et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 678-685
58. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoeti administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924
59. Scalera F, Kielstein JT, Martens-Lobenhoffer J et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 2005; 16: 892-898
60. Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999; 33:894- 899
61. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1615
62. McClellan WM, Flanders WD, Langston RD et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002; 13: 1928-1936
63. Astor BC, Arnett DK, Brown A et al. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 2004; 43: 836-835
64. Silverberg DS, Wexler D, Blum M et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int 2001; 3: S236-S240
65. Silverberg DS, Wexler D, Blum M et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18: 141-146
66. Pascual J, Teruel JL, Moya JL et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280-287
67. Portoles J, Torralbo A, Martin P et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548
68. Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure.AmJKidneyDis 2000; 35: 250-256
69. Roger SD, McMahon LP, Clarkson A et al. Effects of early and late interventionwith epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156
70. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J AmSoc Nephrol 2005; 16: 2180- 2189
71. Levin A, Djurdjev O, Thompson C et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811
72. Ritz E, Laville M, Bilous RW et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) study. Am J Kidney Dis2007; 49: 194-207
73. Van Der Meer P, Lipsic E, Henning RH et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 2004; 6: 853- 859
74. Moon C, KrawczykM,AhnDet al.Erythropoietin reducesmyocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003; 100: 11612-11617
75. Parsa CJ, Kim J, Riel RU et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 2004; 279: 20655-20662
76. Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999- 1007
77. Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin protects the myocardium from ischemia reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100: 4802-4806
78. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int1999; 55: 808-820
79. Abdelrahman M, Sharples EJ, McDonald MC et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004; 22: 63-69
80. Vesey DA, Cheung C, Pat B et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004; 19: 348- 355
81. Spandou E, Tsouchnikas I, Karkavelas G et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/ reperfusion model. Nephrol Dial Transplant 2006; 21: 330- 336
82. Logar CM, Brinkkoetter PT,Krofft RDet al.Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007; 72: 489-498
83. Bahlmann FH, Song R, Boehm SM et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 100: 1006-1012
84. Menne J, Park JK, Shushakova N et al. Continuous erythropoietin receptor activation affects different pathways of diabetic renal injury. J Am Soc Nephrol 2007; 18: 2046-2053
85. Gouva C, Nikolopoulos P, Ioannidis JP et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760
86. Garcia DL, Anderson S, Rennke HG et al. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 1988; 85: 6142-6146
87. Tong Z, Yang Z, Patel S et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA 2008; 105: 6998-7003